Effectiveness and Safety of Colorectal Cancer Screening Via Fecal Occult Blood Testing: A Systematic Review and Meta-Analysis.

J Gastrointest CancerSep 23, 2026 (epub)
Clinical ResearchGastroenterologyOncology (Medical)Open access

Mayra Calil Jorge Frankenfeld, Giovanna Camarotto Patah, Luiza Teixeira Soares et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis assessed the effectiveness of colorectal cancer screening via fecal occult blood tests in adults aged 45-75. The analysis found that screening reduced colorectal cancer-specific mortality (RR = 0.89, 95% CI 0.84-0.94) but did not affect all-cause mortality (RR = 1.00, 95% CI 0.99-1.01).

Key findings

  • Screening reduced colorectal cancer-specific mortality by 11% (RR = 0.89, 95% CI 0.84-0.94).
  • No difference in all-cause mortality was observed (RR = 1.00, 95% CI 0.99-1.01).
  • Non-RCTs indicated a significant reduction in CRC-specific mortality with FIT (RR = 0.21, 95% CI 0.20-0.21).
  • RCTs showed no significant effect on CRC incidence or stage IV CRC incidence.

Why it matters

Understanding the effectiveness of colorectal cancer screening is crucial for public health strategies aimed at reducing cancer mortality. This review highlights the potential benefits of fecal occult blood tests in improving outcomes for colorectal cancer.

Source

PubMed · PMID 42776379Free full text on PubMed Central

Published in J Gastrointest Cancer. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.